Orthofix Medical (NASDAQ:OFIX – Get Free Report) issued its quarterly earnings results on Monday. The medical device company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.44, FiscalAI reports. Orthofix Medical had a negative net margin of 7.41% and a negative return on equity of 14.05%. The firm had revenue of $207.86 million for the quarter, compared to analyst estimates of $210.52 million.
Orthofix Medical Price Performance
Shares of NASDAQ OFIX opened at $7.87 on Monday. The firm has a 50-day simple moving average of $9.29 and a 200-day simple moving average of $10.99. The stock has a market capitalization of $320.57 million, a price-to-earnings ratio of -5.11 and a beta of 0.66. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. Orthofix Medical has a 52 week low of $7.81 and a 52 week high of $16.42.
Analyst Ratings Changes
A number of brokerages have commented on OFIX. Weiss Ratings cut Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 3rd. Canaccord Genuity Group decreased their target price on Orthofix Medical from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $14.75.
View Our Latest Analysis on OFIX
About Orthofix Medical
Orthofix Medical Inc is a medical device company focused on spinal and orthopedic solutions. The company develops, manufactures and distributes products designed to help treat spinal disorders, support bone healing and address orthopedic trauma and related musculoskeletal conditions.
Its product portfolio includes spinal fixation and interbody systems, biologics and bone-grafting products, bone growth stimulation devices, and technologies for spinal motion preservation and deformity correction.
Read More
- Five stocks we like better than Orthofix Medical
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Orthofix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix Medical and related companies with MarketBeat.com's FREE daily email newsletter.
